** Shares of Orthocell Ltd OCC.AX rise 3.8% to A$1.52, their highest since April 10
** The biotech firm receives regulatory approval from Health Canada to commence sales of its flagship nerve repair product Remplir in Canadian market
** Co says first sales expected in the second half of 2025
** Stock up 11.1% YTD, including moves in the current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。